A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the T… (NCT06590259) | Clinical Trial Compass
RecruitingPhase 2
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
China20 participantsStarted 2024-03-12
Plain-language summary
The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to clarify its application value by comparing preoperative and postoperative immune indicators.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18-75 years, gender not specified;
✓. Pathologically or clinically confirmed colorectal cancer liver metastases, with liver lesions unsuitable for surgical resection or intolerance or refusal of surgical resection;
✓. In the case of an unresectable primary tumor or recurrence, the absence of serious complications such as bleeding or obstruction;
✓. Failure of first-line treatment, with disease progression or new liver metastases;
✓. No more than 5 liver lesions, with single lesion diameter ≤ 3cm;
✓. For those who have received previous chemotherapy, radiotherapy or local liver treatment, the interval from the last systemic treatment or local liver treatment should be at least 1 month;
✓. Child-Pugh A or B; bilirubin ≤ 3.0 mg/dL, creatinine ≤ 2.5 mg/dL, white blood cell count ≥ 2.0 ×10\^9/L, platelets ≥ 100 ×10\^9/L;
✕. Refractory massive ascites, pleural effusion or cachexia;
✕. Unable to cooperate with treatment;
✕. Any other factors deemed inappropriate for inclusion or that may affect the subject's participation in the study, as determined by the investigator.